Effects of a Food Supplement on Quality of Life in Patients With Chronic Obstructive Pulmonary Disease. (EPOCAT)

Arafarma

Status

Completed

Conditions

Chronic Obstructive Pulmonary Disease

Treatments

Dietary Supplement: Placebo

Dietary Supplement: Food supplement

Study type

Interventional

Funder types

Industry

Identifiers

NCT04815499

ARA-EXP/ARA-2019-01

Details and patient eligibility

About

It has been demonstrated that consequences of malnutrition affect a situation of risk and have negative effects on the evolution of chronic obstructive pulmonary disease (COPD), accompanied by higher morbidity and mortality. The impact of malnutrition on the respiratory system affects the respiratory muscles, the lung parenchyma, and the immune system. In summary, the risk of complications can lead to a worsening of the quality of life of the COPD patient. Also, dyspnea as the main symptom of COPD is the one that produces the greatest loss of quality of life, especially in older patients. The components of our authorized food supplement improve the quality of life of the patient. These components maintain the strength and energy of the patient, help the body to recover and regain its optimal state, help improve the immune system, help reduce the side effects of therapies associated with the control or cure of cancer and help correct nutritional deficiencies. This is the reason why this experimental study aims to improve the quality of life in patients with COPD with a CAT score>15.

Full description

This study is developed in two phases: pilot phase and experimental phase. The pilot phase is preliminary and progressive in order to demonstrate a sufficient effect of improving the quality of life of patients and to be able to continue in an experimental phase with more investigational sites and more patients, and to evaluate other secondary objectives.

Once the pilot phase is finished, an intermediate analysis of the results will be carried out to evaluate the magnitude of the variation in quality of life at 3, 6, 9 and 12 months. If the expected success expectations are achieved and it is approved by the Ethics Committee, the study will continue to the experimental phase.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults: men and women ≥ 18 years.
Patients with a medical diagnosis of COPD based on a recent spirometry.
Patients with a CAT score> 15, affecting COPD symptoms in a moderate-high way in the daily life of these patients.
Minimum clinical stability period of 4 weeks before the start of the study.
Patients who are trained to give informed consent.
Patients must agree to perform study visits and procedures with precise instructions.

Exclusion criteria

BMI ≥ 40.
Comorbidities, which due to their severity or progression, may interfere with the results, such as cancer, hematological disorders, severe heart or liver failure, kidney failure on dialysis, tuberculosis (TB) or AIDS, or other pulmonary pathologies such as pulmonary thromboembolism ( PE), pulmonary fibrosis, or relevant bronchiectasis.
In Pulmonary Rehabilitation treatment or in treatment for smoking.
Pregnancy or breastfeeding.
Impossibility of the patient, due to a medical condition, to follow the study.